Health care reform won't take its final form for at least a few weeks. But some sectors in the medical delivery system already are poised to gain from new legislation, regardless of how it turns out. Two of them are at distant ends of the biopharmaceutical spectrum. At one end are contract research organizations, or CROs, which conduct clinical trials of new drugs for biopharma companies. At the other end are pharmacy benefit managers (PBMs). They